Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Novel diabetes subgroups.

Feher MD, Munro N, Russell-Jones D, de Lusignan S, Khunti K.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):439. doi: 10.1016/S2213-8587(18)30126-8. No abstract available.

PMID:
29803263
2.

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol.

Hinton W, Feher M, Munro N, de Lusignan S.

Diabetes Ther. 2018 Jun;9(3):1397-1402. doi: 10.1007/s13300-018-0390-8. Epub 2018 Mar 31.

3.

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.

Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC; FIELD investigators.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26.

PMID:
29496472
4.

Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.

Feher M, Gaszner B, Tamas A, Gil-Martinez AL, Fernandez-Villalba E, Herrero MT, Reglodi D.

Neurotox Res. 2018 May;33(4):702-715. doi: 10.1007/s12640-017-9841-7. Epub 2017 Dec 11.

PMID:
29230633
5.

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.

McGovern A, Feher M, Munro N, de Lusignan S.

Diabetes Ther. 2017 Apr;8(2):365-376. doi: 10.1007/s13300-017-0254-7. Epub 2017 Mar 21.

6.

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.

Feher M, Vega-Hernandez G, Mocevic E, Buysse B, Myland M, Power GS, Nystrup Husemoen LL, Kim J, Witte DR.

Diabetes Ther. 2017 Apr;8(2):417-431. doi: 10.1007/s13300-017-0241-z. Epub 2017 Mar 9.

7.

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).

McGovern A, Feher M, Munro N, de Lusignan S.

Diabetes Ther. 2017 Apr;8(2):355-363. doi: 10.1007/s13300-017-0229-8. Epub 2017 Jan 30.

8.

Accumulation of Metals in Juvenile Carp (Cyprinus carpio) Exposed to Sublethal Levels of Iron and Manganese: Survival, Body Weight and Tissue.

Harangi S, Baranyai E, Fehér M, Tóth CN, Herman P, Stündl L, Fábián I, Tóthmérész B, Simon E.

Biol Trace Elem Res. 2017 May;177(1):187-195. doi: 10.1007/s12011-016-0854-5. Epub 2016 Sep 28.

PMID:
27683024
9.

[Operation - rehabilitation - employment].

Mészáros G, Fehér M, Borbély C.

Ideggyogy Sz. 2016 Sep 30;69(9-10):349-354. doi: 10.18071/isz.69.0349. Hungarian.

PMID:
29638101
10.

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

Li SW, Liu Y, Sampson PB, Patel NK, Forrest BT, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Hodgson R, Beletskaya I, Mao G, Mason JM, Wei X, Luo X, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4625-4630. doi: 10.1016/j.bmcl.2016.08.063. Epub 2016 Aug 23.

PMID:
27592744
11.

Precision evaluation of panoramic morphometric index measurement's performed by experienced clinicians and dental students.

Feher M, Kuki A, Mohacsi R, Birinyi L, Angyal J.

Fogorv Sz. 2016 Sep;109(3):81-87. English, Hungarian.

PMID:
29693953
12.

Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.

Bain SC, Feher M, Russell-Jones D, Khunti K.

Diabetes Obes Metab. 2016 Dec;18(12):1157-1166. doi: 10.1111/dom.12760. Epub 2016 Sep 14. Review.

PMID:
27491724
13.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Plotnikova O, Awrey DE, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Fletcher GC, Mak TW, Bray MR, Pauls HW.

ACS Med Chem Lett. 2016 May 6;7(7):671-5. doi: 10.1021/acsmedchemlett.5b00485. eCollection 2016 Jul 14.

14.

Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.

Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3562-6. doi: 10.1016/j.bmcl.2016.06.021. Epub 2016 Jun 9.

PMID:
27335255
15.

Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes.

Feher MD, Brazier J, Schaper N, Vega-Hernandez G, Nikolajsen A, Bøgelund M.

BMJ Open Diabetes Res Care. 2016 Apr 29;4(1):e000192. doi: 10.1136/bmjdrc-2016-000192. eCollection 2016.

16.

Hypoglycemia, diabetes therapies and driving categories in type 2 diabetes.

Feher MD, Langerman H, Evans M.

Curr Med Res Opin. 2016 Jun;32(6):1005-12. doi: 10.1185/03007995.2016.1155981. Epub 2016 Mar 24.

PMID:
26986544
17.

Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease.

Baldwin EJ, Harrington DJ, Sampson B, Feher MD, Wierzbicki AS.

Int J Clin Pract. 2016 Mar;70(3):229-35. doi: 10.1111/ijcp.12770. Epub 2016 Jan 22.

PMID:
26799636
18.

In vivo NIRS monitoring in pig Spinal Cord tissues.

Tsiakaka O, Terosiet M, Romain O, Histace A, Benali H, Pradat PF, Vallette F, Feher M, Feruglio S.

Conf Proc IEEE Eng Med Biol Soc. 2015 Aug;2015:4262-5. doi: 10.1109/EMBC.2015.7319336.

PMID:
26737236
19.

Willingness To Pay For Improved Clinical Outcomes And Reduced Treatment Burden Associated With Insulin Treatment In People With Type 2 Diabetes In South America.

Feher M, Nikolajsen A, Vega G, Boegelund M, Brazier J.

Value Health. 2015 Nov;18(7):A866. doi: 10.1016/j.jval.2015.09.518. Epub 2015 Oct 20. No abstract available.

20.

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.

Liu Y, Lang Y, Patel NK, Ng G, Laufer R, Li SW, Edwards L, Forrest B, Sampson PB, Feher M, Ban F, Awrey DE, Beletskaya I, Mao G, Hodgson R, Plotnikova O, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.

J Med Chem. 2015 Apr 23;58(8):3366-92. doi: 10.1021/jm501740a. Epub 2015 Apr 3.

PMID:
25763473
21.

The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

Sampson PB, Liu Y, Forrest B, Cumming G, Li SW, Patel NK, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Mao G, Plotnikova O, Hodgson R, Beletskaya I, Mason JM, Luo X, Nadeem V, Wei X, Kiarash R, Madeira B, Huang P, Mak TW, Pan G, Pauls HW.

J Med Chem. 2015 Jan 8;58(1):147-69.

PMID:
25723005
22.

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.

Laufer R, Ng G, Liu Y, Patel NK, Edwards LG, Lang Y, Li SW, Feher M, Awrey DE, Leung G, Beletskaya I, Plotnikova O, Mason JM, Hodgson R, Wei X, Mao G, Luo X, Huang P, Green E, Kiarash R, Lin DC, Harris-Brandts M, Ban F, Nadeem V, Mak TW, Pan GJ, Qiu W, Chirgadze NY, Pauls HW.

Bioorg Med Chem. 2014 Sep 1;22(17):4968-97. doi: 10.1016/j.bmc.2014.06.027. Epub 2014 Jun 23.

PMID:
25043312
23.

The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Sampson PB, Liu Y, Patel NK, Feher M, Forrest B, Li SW, Edwards L, Laufer R, Lang Y, Ban F, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Mason JM, Wei X, Kiarash R, Green E, Qiu W, Chirgadze NY, Mak TW, Pan G, Pauls HW.

J Med Chem. 2015 Jan 8;58(1):130-46. doi: 10.1021/jm5005336. Epub 2014 Jun 24.

PMID:
24867403
24.

The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.

Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.

J Med Chem. 2013 Aug 8;56(15):6069-87. doi: 10.1021/jm400380m. Epub 2013 Jul 26.

PMID:
23829549
25.

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus.

Feher M, Greener M, Munro N.

Diabetes Metab Syndr Obes. 2013;6:11-5. doi: 10.2147/DMSO.S35053. Epub 2013 Jan 10.

26.

Numerical errors in minimization based binding energy calculations.

Feher M, Williams CI.

J Chem Inf Model. 2012 Dec 21;52(12):3200-12. doi: 10.1021/ci300298d. Epub 2012 Nov 28.

PMID:
23146112
27.

Novel mutations of ABCA1 transporter in patients with Tangier disease and familial HDL deficiency.

Fasano T, Zanoni P, Rabacchi C, Pisciotta L, Favari E, Adorni MP, Deegan PB, Park A, Hlaing T, Feher MD, Jones B, Uzak AS, Kardas F, Dardis A, Sechi A, Bembi B, Minuz P, Bertolini S, Bernini F, Calandra S.

Mol Genet Metab. 2012 Nov;107(3):534-41. doi: 10.1016/j.ymgme.2012.08.005. Epub 2012 Aug 18.

PMID:
22959828
28.

Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study.

Mackness B, Marsillach J, Elkeles RS, Godsland IF, Feher MD, Rubens MB, Flather MD, Humphries SE, Cooper J, Mackness M.

Dis Markers. 2012;33(2):101-12. doi: 10.3233/DMA-2012-0910.

29.

Automated generation of turn mimetics: proof of concept study for the MC4 receptor.

Baber JC, Lowe R, Saunders J, Feher M.

Bioorg Med Chem. 2012 Jun 1;20(11):3565-74. doi: 10.1016/j.bmc.2012.04.001. Epub 2012 Apr 13.

PMID:
22551631
30.

Numerical errors and chaotic behavior in docking simulations.

Feher M, Williams CI.

J Chem Inf Model. 2012 Mar 26;52(3):724-38. doi: 10.1021/ci200598m. Epub 2012 Mar 13.

PMID:
22379951
31.

QTc prolongation and diabetes therapies.

Watters K, Munro N, Feher M.

Diabet Med. 2012 Mar;29(3):290-2. doi: 10.1111/j.1464-5491.2011.03520.x. No abstract available.

PMID:
22060961
32.

Structural chemistry of the histone methyltransferases cofactor binding site.

Campagna-Slater V, Mok MW, Nguyen KT, Feher M, Najmanovich R, Schapira M.

J Chem Inf Model. 2011 Mar 28;51(3):612-23. doi: 10.1021/ci100479z. Epub 2011 Mar 3.

PMID:
21366357
33.

Can protein biomarkers provide an index of coronary artery calcification in patients with Type 2 diabetes?

Godsland IF, Pavitt D, Okoturo O, Edwards RJ, Rubens MB, Feher MD, Flather MD, Elkeles RS; PREDICT Study Group.

Atherosclerosis. 2010 Dec;213(2):570-2. doi: 10.1016/j.atherosclerosis.2010.09.002. Epub 2010 Sep 15.

PMID:
20880528
34.

Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy.

Rüether K, Baldwin E, Casteels M, Feher MD, Horn M, Kuranoff S, Leroy BP, Wanders RJ, Wierzbicki AS.

Surv Ophthalmol. 2010 Nov-Dec;55(6):531-8. doi: 10.1016/j.survophthal.2010.03.007. Epub 2010 Sep 20. Review.

PMID:
20850855
35.

Reducing docking score variations arising from input differences.

Feher M, Williams CI.

J Chem Inf Model. 2010 Sep 27;50(9):1549-60. doi: 10.1021/ci100204x.

PMID:
20698562
36.

Fixed-dose combinations in diabetes--do they improve medication adherence?

Feher MD, Munro N, Watters K.

Diabet Med. 2010 Jul;27(7):735-6. doi: 10.1111/j.1464-5491.2010.03023.x. No abstract available. Erratum in: Diabet Med. 2010 Aug;27(8):969.

PMID:
20636951
37.

The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease.

Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher MD, Wierzbicki AS.

J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):954-7. doi: 10.1136/jnnp.2008.161059. Epub 2010 Jun 14.

PMID:
20547622
38.

Forecasting CYP2D6 and CYP3A4 Risk with a Global/Local Fusion Model of CYP450 Inhibition.

Ewing T, Feher M.

Mol Inform. 2010 Jan 12;29(1-2):127-41. doi: 10.1002/minf.200900040.

PMID:
27463854
39.

Effect of input differences on the results of docking calculations.

Feher M, Williams CI.

J Chem Inf Model. 2009 Jul;49(7):1704-14. doi: 10.1021/ci9000629.

PMID:
19530660
40.

Insulin for type 2 diabetes: choosing a second-line insulin regimen.

Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N.

Int J Clin Pract. 2008 Nov;62(11):1647-53. doi: 10.1111/j.1742-1241.2008.01909.x.

41.

Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures.

De Lorenzo F, Collot-Teixeira S, Boffito M, Feher M, Gazzard B, McGregor JL.

Curr Med Chem. 2008;15(28):2991-9. Review.

PMID:
19075647
42.

Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes.

Munro N, Feher MD.

Br J Gen Pract. 2008 Aug;58(553):531-3. doi: 10.3399/bjgp08X319684. No abstract available.

43.

Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study.

Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, Humphries SE, Richmond W, Flather MD; PREDICT Study Group.

Eur Heart J. 2008 Sep;29(18):2244-51. doi: 10.1093/eurheartj/ehn279. Epub 2008 Jun 23.

44.

The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjects.

Salpea KD, Gable DR, Cooper JA, Stephens JW, Hurel SJ, Ireland HA, Feher MD, Godsland IF, Humphries SE.

Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):140-5. doi: 10.1016/j.numecd.2008.02.009. Epub 2008 Jun 13.

PMID:
18555673
45.

The effect of numerical error on the reproducibility of molecular geometry optimizations.

Williams CI, Feher M.

J Comput Aided Mol Des. 2008 Jan;22(1):39-51. Epub 2007 Dec 6.

PMID:
18058242
46.

The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies.

Feher M, Gao Y, Baber JC, Shirley WA, Saunders J.

Bioorg Med Chem. 2008 Jan 1;16(1):422-7. Epub 2007 Sep 18.

PMID:
17920281
47.

The progress of coronary heart disease in Type 2 diabetes as measured by coronary calcium score from electron beam computed tomography (EBCT): the PREDICT study.

Elkeles RS, Godsland IF, Rubens MB, Feher MD, Nugara F, Flather MD.

Atherosclerosis. 2008 Apr;197(2):777-83. Epub 2007 Oct 24.

PMID:
17920067
48.

[Treatment of spastic upper limb with botulinum toxin].

Dénes Z, Fehér M, Várkonyi A.

Ideggyogy Sz. 2007 May 30;60(5-6):245-50. Hungarian.

PMID:
17578272
49.

Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists.

Lanier MC, Feher M, Ashweek NJ, Loweth CJ, Rueter JK, Slee DH, Williams JP, Zhu YF, Sullivan SK, Brown MS.

Bioorg Med Chem. 2007 Aug 15;15(16):5590-603. Epub 2007 May 17.

PMID:
17561404
50.

Functional genomics of calcium channels in human melanoma cells.

Deli T, Varga N, Adám A, Kenessey I, Rásó E, Puskás LG, Tóvári J, Fodor J, Fehér M, Szigeti GP, Csernoch L, Tímár J.

Int J Cancer. 2007 Jul 1;121(1):55-65.

Supplemental Content

Support Center